BenevolentAI vs Insitro

Insitro has a disclosed valuation of $2.2B, while BenevolentAI's valuation is not publicly available, making a direct size comparison difficult. Insitro employs 300 people.

Insitro has raised more in total funding at $743M, compared to BenevolentAI's $292M — a gap of $451M. Combined, the two companies have completed 3 known funding rounds.

Insitro holds the higher Awaira Score at 73/100, compared to BenevolentAI's 62/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 11-point gap that reflects meaningful differences in scale or traction.

BenevolentAI was founded by Joanna Shields in 2013. Insitro was founded by Daphne Koller in 2018. Visit each company's profile on Awaira for a full founder biography.

BenevolentAI: BenevolentAI applies machine learning to drug discovery, using knowledge graph technology and predictive AI models to identify novel drug candidates and repurpose existing compounds for new therapeutic applications. The London-based company has built a proprietary biomedical knowledge graph containing billions of data points extracted from scientific literature, clinical trial data, and genomic databases, which feeds its target identification and molecule generation pipelines.\n\nThe company went public on Euronext Amsterdam in 2022 via a SPAC merger with Odyssey Acquisition, having previously raised approximately $292 million in private funding from backers including SoftBank, Woodford Investment Management, and Mayfair Equity Partners. BenevolentAI has clinical-stage programs in atopic dermatitis and amyotrophic lateral sclerosis, developed from AI-generated hypotheses that were subsequently validated in wet lab experiments and progressed into human trials.\n\nBenevolentAI operates in the AI drug discovery sector alongside Recursion Pharmaceuticals, Exscientia, and Insilico Medicine. The company faces the inherent challenge of all computational drug discovery platforms in demonstrating that AI-generated candidates can survive clinical attrition at higher rates than traditionally discovered drugs. The platform is considered one of the more mature AI drug discovery systems in Europe, with the longest track record of moving AI-generated hypotheses into clinical development. Insitro: Insitro is an AI-driven drug discovery company founded in 2018 that applies machine learning to accelerate pharmaceutical development. The company combines computational biology, artificial intelligence, and wet-lab experimentation to identify and validate drug targets more efficiently than traditional methods. Insitro's platform uses proprietary algorithms to analyze complex biological data, predict drug efficacy and safety profiles, and optimize candidate selection across therapeutic areas including metabolic disease, oncology, and immunology. The company has raised $743 million across multiple funding rounds, achieving a valuation of $2.2 billion as of its Series C stage. This positions Insitro among well-capitalized AI healthcare startups addressing the structural inefficiencies in drug discovery. The company partners with pharmaceutical institutions to apply its technology to their pipelines, leveraging both internal discovery programs and collaborations. Insitro's competitive approach differs from pure software platforms by integrating experimental validation, reducing the translation gap between computational predictions and real-world drug performance. The company operates in a crowded but expanding market of AI drug discovery platforms competing against both established pharma AI initiatives and other venture-backed startups. Its growth trajectory reflects investor confidence in AI-enabled drug discovery models, though clinical validation remains ongoing for internally developed candidates. Insitro uniquely combines machine learning with integrated wet-lab capabilities rather than operating as pure software, bridging computational predictions to experimental validation.

BenevolentAI was founded first in 2013, giving it 5 years of additional market experience. Insitro was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

BenevolentAI has approximately 100-500 employees, while Insitro has approximately 300. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, BenevolentAI and Insitro are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.